Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Core Viewpoint - ADC Therapeutics SA (ADCT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for ADC Therapeutics suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7][9]. - The upgrade to Zacks Rank 2 places ADC Therapeutics in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, ADC Therapeutics is expected to earn -$1.47 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 15% over the past three months [8].

Core Insights - ADC Therapeutics (NYSE:ADCT) is highlighted as a promising investment opportunity, particularly in the context of its lymphoma treatment developments [1][2] - Recent positive interim Phase Ib data from the LOTIS-7 trial has led to reaffirmed buy ratings from analysts, with price targets set at $10.00 by Guggenheim and $5.00 by RBC Capital [1][2] Trial Results - The LOTIS-7 trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% among 49 efficacy-evaluable patients, indicating strong efficacy for ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma [3] - The trial results support the potential of ZYNLONTA and glofitamab as leading bispecific antibody-based combinations for patients with 2L+ DLBCL [3] Regulatory Approvals - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma, enhancing its market position [5][6] Company Overview - ADC Therapeutics is a commercial-stage biotech company focused on developing targeted cancer therapies using Antibody-Drug Conjugates (ADCs) and proprietary Pyrrolobenzodiazepine (PBD) technology [6]

Industry Overview - The Russell 2000 Index has reached new highs, indicating a renewed interest in small-cap companies, with an increase of over 13% for the year as market rotation from large-cap stocks accelerates [1][2] - Investors are shifting focus to higher-risk, higher-reward assets, reflecting growing confidence in the economy and corporate sector amid the ongoing US Federal Reserve easing cycle [2][3] - Small caps and penny stocks, previously undervalued, are gaining traction as monetary policy is perceived to be no longer tightening [3][4] Market Sentiment - A third Federal Reserve rate cut and expectations for further easing are driving interest in small companies, with the Russell 2000 Index outperforming the S&P 500 as the year ends [4] - Analysts from major financial institutions anticipate that the rotation towards small-cap stocks will continue into 2026 [4][5] Investment Strategy - The article highlights the methodology for selecting the best multibagger penny stocks, focusing on those trading under $5 with over 100% upside potential and popularity among elite hedge funds [7][8] - The strategy has historically outperformed the market, returning 427.7% since May 2014, significantly beating its benchmark [8] Company Highlights ADC Therapeutics S.A. (NYSE:ADCT) - ADC Therapeutics is identified as a top multibagger penny stock with a current share price of $4.18 and an analyst upside potential of 102.11% [9] - The company has received positive ratings from analysts, with a price target of $10.00 from Guggenheim and $5.00 from RBC Capital based on promising trial data [9][10] - The LOTIS-7 trial results show an overall response rate of 89.8% and a complete response rate of 77.6% for its drug ZYNLONTA, which has received accelerated FDA approval [11][13] Repay Holdings Corporation (NASDAQ:RPAY) - Repay Holdings is another top multibagger penny stock, currently priced at $3.40 with an upside potential of 105.88% [15] - The company is focusing on expanding its market presence and enhancing technology offerings to drive future growth, moving from negative growth and margin pressures [16][17] - Repay Holdings aims to capitalize on the $5.6 trillion market opportunity, particularly in non-discretionary transactions, while achieving over 50% free cash flow [19][20]

Core Viewpoint - ADC Therapeutics SA (ADCT) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Indicators - ADCT shares have increased by 28.57% over the past week, while the Zacks Medical - Biomedical and Genetics industry has remained flat during the same period [6]. - Over the last quarter, ADCT shares rose by 23.68%, and they have surged 123.81% over the past year, significantly outperforming the S&P 500, which increased by only 4% and 14.09% respectively [7]. Trading Volume - The average 20-day trading volume for ADCT is 1,634,451 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for ADCT have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$1.68 to -$1.47 [10]. - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating a positive earnings outlook [10].

Group 1: Snowflake Inc (NYSE:SNOW) - Snowflake reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 [2] Group 2: Other Companies - Net Lease Office Properties (NYSE:NLOP) shares decreased by 14.7% to $25.19 in pre-market trading [4] - Symbotic Inc (NASDAQ:SYM) shares dropped 10.5% to $65.50 following a 10 million share offering announcement [4] - Capricor Therapeutics Inc (NASDAQ:CAPR) shares fell 8.4% to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA (NYSE:ADCT) shares declined 8.1% to $3.63 after reporting updated data from its LOTIS-7 trial [4] - Koninklijke Philips NV (NYSE:PHG) shares decreased by 6.8% to $26.11 in pre-market trading [4] - Omeros Corp (NASDAQ:OMER) shares fell 4.2% to $10.18 [4] - Methanex Corp (NASDAQ:MEOH) shares dropped 3.8% to $35.95 [4]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones increasing by over 250 points, closing up 0.61% at 47,765.87, while the NASDAQ rose 0.07% to 23,430.56, and the S&P 500 gained 0.22% to 6,844.57 [1] - Energy shares saw a notable increase of 1.2%, while information technology stocks fell by 0.6% [1] Company Performance - Macy's Inc reported third-quarter sales of $4.713 billion, a decrease of 0.6% year-over-year, but exceeded analysts' expectations of $4.621 billion. The company also reported adjusted earnings per share of 9 cents [2] Commodity Market - Oil prices rose by 1% to $59.21, gold increased by 0.6% to $4,246.90, silver was up 0.4% to $58.935, and copper saw a significant rise of 3% to $5.4000 [5] European Market - European shares were mostly higher, with the eurozone's STOXX 600 rising by 0.16%, Spain's IBEX 35 Index increasing by 1.55%, while London's FTSE 100 fell slightly by 0.02% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei gaining 1.14%, while Hong Kong's Hang Seng fell by 1.28%, China's Shanghai Composite decreased by 0.51%, and India's BSE Sensex fell by 0.04% [7] Notable Stock Movements - Capricor Therapeutics, Inc. saw a dramatic increase of 291% to $24.87 following positive trial results for its cell therapy [8] - Virax Biolabs Group Limited surged 71% to $0.6709 after announcing clinical progress [8] - Aeva Technologies, Inc. gained 16% to $12.58 after being selected as a LiDAR supplier for a major European OEM [8] - CIMG Inc. shares dropped 35% to $0.1200 due to a reverse stock split announcement [8] - ADC Therapeutics SA fell 29% to $3.2499 after reporting updated trial data [8] - Pure Storage, Inc. decreased by 26% to $69.99 following its third-quarter results [8] Economic Indicators - The S&P Global services PMI declined to 54.1 in November from 54.8, and the composite PMI fell to 54.2 from 54.6 [11] - U.S. industrial production increased by 0.1% month-over-month in September, contrasting with a revised 0.3% decline in August [11] - Private businesses in the U.S. reduced jobs by 32,000 in November, compared to a revised gain of 47,000 in the previous month [11] - U.S. crude oil inventories rose by 0.574 million barrels in the week ending Nov. 28, compared to a 2.774 million barrel gain in the previous week [11]

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Core Viewpoint - ADC Therapeutics SA has announced updated results from the LOTIS-7 clinical trial, highlighting the potential of ZYNLONTA in treating DLBCL (Diffuse Large B-cell Lymphoma) [2][3]. Group 1: Clinical Trial Update - The LOTIS-7 clinical trial results were shared in a press release and are available on the company's website [2]. - The Chief Medical Officer, Mohamed Zaki, will provide detailed insights into the LOTIS-7 clinical trial and its updated results during the call [3]. Group 2: Strategic Overview - Ameet Mallik, the Chief Executive Officer, will present a strategic overview and discuss the opportunity for ZYNLONTA in the DLBCL market [3].

Summary of ADC Therapeutics SA Lotus 7 Update Conference Call Company and Industry Overview - **Company**: ADC Therapeutics SA - **Industry**: Oncology, specifically focusing on therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Key Points and Arguments 1. **Clinical Trial Update**: ADC Therapeutics announced updated results from the LOTIS-7 clinical trial, focusing on the combination of Zynlonta and glofitamab for treating DLBCL [2][10] 2. **Zynlonta's Profile**: Zynlonta is positioned as a single-agent therapy for third-line plus DLBCL, with rapid, deep, and durable efficacy, and manageable safety [4][20] 3. **Market Opportunity**: The potential peak revenue for Zynlonta in DLBCL is estimated to be between $500 million and $800 million, with a broader potential reaching $600 million to $1 billion as it expands into earlier lines of therapy and indolent lymphomas [20][21] 4. **Efficacy Data**: The best overall response rate (ORR) in the LOTIS-7 trial was reported at 89.8%, with a complete response (CR) rate of 77.6% among 49 efficacy-available patients [11][12] 5. **Patient Demographics**: The median age of patients in the study was 70 years, with a range from 26 to 85 years, and a median of one prior line of therapy [12][14] 6. **Safety Profile**: Neutropenia was the most common treatment-emergent adverse event, occurring in 32.7% of patients, consistent with known profiles of the individual drugs [11][14][39] 7. **Combination Therapy Rationale**: The combination of Zynlonta and glofitamab is expected to provide additive or synergistic efficacy due to their complementary mechanisms of action [8][10] 8. **Regulatory Strategy**: ADC Therapeutics plans to submit for regulatory approval and compendia listing following positive results from ongoing trials, with updates expected in 2026 [22][23] Additional Important Information 1. **Treatment Landscape**: The DLBCL treatment landscape is evolving, with a current 60/40 split between complex therapies (e.g., CAR-T, bispecifics) and broadly accessible therapies (e.g., ADCs, monoclonal antibodies) [5][6] 2. **Future Catalysts**: Multiple data catalysts are expected in 2026, including updates from LOTIS-5 and LOTIS-7 trials, which could significantly impact Zynlonta's market potential [21][22] 3. **Durability of Responses**: Among patients achieving CR, 33 out of 38 maintained their response as of the data cutoff, indicating promising durability [11][19] 4. **Comparative Efficacy**: The trial showed strong efficacy in both relapsed (100% ORR, 91.6% CR) and primary refractory (80% ORR, 64% CR) patient populations [18][30] 5. **Enrollment Trajectory**: The company is on track to complete enrollment of 100 patients in the LOTIS-7 trial by the first half of 2026, with a focus on maintaining a balanced patient population [43] This summary encapsulates the critical insights from the ADC Therapeutics conference call, highlighting the company's strategic direction, clinical trial outcomes, and market potential in the oncology sector.